

2017 Full-year results

Conference presentation for investors, analysts & media

Basel, 15 February 2018

straumanngroup

Disclaimer

This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country.

2017 highlights

Marco Gadola, CEO

straumanngroup

Growth story continues

REVENUE	REVENUE GROWTH	EBIT MARGIN ²
CHF 1112m <small>2016: CHF 918m</small>	+16% organic ¹	25.7%
Driven by double-digit growth across all regions and businesses.	Q4: +18% organic; +28% in CHF	Operational leverage drives EBIT margin improvement. Underlying EBITDA margin rises to 29.3%
KEY DRIVERS	TECHNOLOGY	OUTLOOK ³
Total solutions	Digital power base	Growth story
Premium business driven by Straumann BLT. Dynamic growth in non-premium driven by Neodent and Medentika.	Dental Wings and ClearCorrect acquired; investment in Rapid Shape; strategic partnerships to support implant, restorative & orthodontics businesses.	...continues. Low double-digit organic growth expected in 2018 with further EBITDA margin improvement.

¹ Organic growth – i.e. excluding the effects of currency fluctuations and acquired/divested business activities

² Excluding exceptionals

³ Guidance expectations barring unforeseen events/circumstances


Stream of launches in 2107



5

Intense M&A activity to expand scope, distribution and technology platform

Partner	Stake	Rationale
Medentika	51% (consolidated)	Further penetrate the non-premium implant & abutment segment
Dental Wings	100%	Accelerate development of digital platforms and equipment
ClearCorrect	100%	Enter orthodontics
Geniova	38%	
Rapid Shape	35%	Access to 3D printing technology
3Shape	Partnership	Distribute high-end intraoral scanners
Rodo Medical	30%	Innovative fixation devices
Loop Digital Solutions	100%	Online referral platform
Distributors in Turkey, Portugal, South Africa	50-100%	Gain share in high-growth markets




6

straumanngroup


Digital powers acceleration in Q4

Organic growth year-on-year (in %)



7



The essence of a successful business year




8

¹ Adjusted for exceptionals one-time tax effects in 2016 and 2017.

straumanngroup



Growing share in an attractive market



11

¹ Market data based on Renub Research, Marketsandmarkets, Goldman Sachs, and Straumann estimates.

² Implant dentistry market segment includes implant fixtures, abutments and related instruments; information based on DRG and Straumann survey

straumanngroup


Business and regional review

Peter Hackel, CFO


straumanngroup

Double-digit expansion in all regions

Revenue development (CHFm, rounded)



Regional share of organic growth



13

straumanngroup

EMEA and North America – growth heavyweights


EMEA



North America



Revenue change (organic)




- EMEA gains further momentum in Q4
- Digital sales and strong demand in the Middle East = main drivers of sequential acceleration
- Key growth contributors: Germany, Italy, and France
- New subsidiary in Iran gaining traction
- Double-digit growth in premium and non-premium implant businesses
- BLT and comprehensive prosthetic range help win new customers
- ClearCorrect and Dental Wings consolidated since 1 October 2017 and add 3% points to growth


14

straumanngroup

Strong Asia Pacific – solid pace in Latin America



Latin America



- Double-digit increases across all subsidiaries
- Performance fueled by China and Japan
- We obtained key approvals and launched the Straumann premium brand in India
- Solid Q4 in Brazil following Neodent GM launch in Q3
- Store network in Brazil expanded
- Dynamic growth continues in Mexico
- New subsidiaries in Argentina, Colombia, and Chile performed well

15

straumanngroup

Double-digit growth across all businesses

Implants

++

Restorative & Digital

+++

Biomaterials

++

16

straumanngroup

Key financials at a glance

in CHF m (rounded)	FY 2017			FY 2016			Δ % / bps excl. Exceptionals
	Reported	Exceptionals	excl. Exceptionals	Reported	Exceptionals	excl. Exceptionals	
Revenue	1112.1			917.5			
Organic growth in %	15.7%			13.1%			
Gross profit	840.5	(2.0)	842.4	718.5			17%
margin	75.6%		75.8%	78.3%			(250 bps)
EBITDA	323.5		325.5	259.2			26%
margin	29.1%		29.3%	28.3%			100 bps
EBIT	283.6		285.6	227.2			26%
margin	25.5%		25.7%	24.8%			90 bps
Net financial result	(19.3)	(16.3)	(3.1)	(3.3)			
Gain on consolidation	68.9	68.9	0.0	0.0			
Share of result of associates	(9.7)			(1.6)			
Taxes	(47.8)	1.9	(49.7)	7.4	42.8	(35.4)	
Net profit	275.6			229.6			20%
margin	24.8%			25.0%			(20 bps)
Basic EPS	17.61			14.68			
Free cash flow	144.7			138.7			4%
margin	13.0%			15.1%			


Exceptional effects in 2017: the Medentika business combination resulted in inventory revaluation expenses of CHF 2m (COGS) and a CHF 25m consolidation gain below the EBIT line. The Dental Wings takeover resulted in a consolidation gain of CHF 44m. A loan revaluation led to an impairment expense of CHF 16m in the financial result. In 2016, net profit benefitted from a one-time effect of CHF 43m related to the capitalization of deferred tax assets in Brazil.

17

straumanngroup

Business mix and capacity expansion squeeze gross margin

Change in %




18

¹ Inventory revaluation expenses of CHF 2 million related to the Medentika business combination.

straumanngroup

Underlying profitability improves; EBITDA margin expands 80bps

In %



19

straumanngroup

Valuable assets acquired for future growth

<i>in CHF m (rounded)</i>	FY 2017	H1 2017	H2 2017	FY 2016	Δ % / bps 2017 vs. 2016
EBITDA (reported) margin	323.5 29.1%	156.1 28.7%	167.5 29.4%	259.2 28.3%	
Depreciation	25.0	11.9	13.0	22.9	9%
Total amortization	14.9	6.3	8.6	9.2	63%
Regular amortization	4.9	1.9	3.0	3.2	56%
Amortization (of acquired intangibles)	10.0	4.4	5.6	6.0	67%
- Neodent	6.5	3.3	3.2	6.0	
- Medentika	1.7	0.8	0.9		
- Dental Wings	1.2		1.2		
- Equinox	0.5	0.3	0.3		
- ClearCorrect ¹					
EBIT (reported) margin	283.6 25.5%	137.8 25.4%	145.8 25.6%	227.2 24.8%	25% 70 bps
Exceptionals	-2.0	-2.0			
EBIT (excl. exceptionals) margin	285.6 25.7%	139.8 25.7%	145.8 25.6%	227.2 24.8%	26% 90 bps


20

¹ Purchase price allocation process for ClearCorrect ongoing

straumanngroup

EBIT margin rises 70bps despite higher amortization charges

In %




21

straumanngroup

Underlying net profit surges 27%

In CHF m




¹ In 2016, net profit was lifted by a one-time effect of CHF 43m, related to the capitalization of deferred tax assets in Brazil.

22

straumanngroup

Free-cash-flow reflects investments in production, geographic and portfolio expansion

In CHF m



23

Chart shows cash-relevant changes January-December 2017, compared with the same period in 2016.

straumanngroup

Strategy in action moving forward

Marco Gadola, CEO

straumanngroup

Our strategic priorities



Drive our high performance STMN Group culture and organization



Target unexploited growth markets & segments




Expand scope to become a **Total Solution Provider for esthetic dentistry**






25

Increased diversity as global team grows 29% due to geographic and business expansion



Drive our high performance STMN Group culture and organization



APAC 10%


CH (incl. HQ) 21%

Rest of EMEA 24%

LATAM 26%

NAM 19%

Headcount development (pro forma¹)



2013: 2217

2014: 2387

2015: 3471


2016: 3797

2017: 3797

Total increase: +1084



Total headcount: 4'881

- +479 due to acquisitions
- +605 internal growth
- +329 in Production
- +241 in Sales
- +153 in Switzerland



26

¹ Including Dental Wings and ClearCorrect, consolidated as of 1 October 2017



Neodent – a driving force



A **top-5** producer of dental implants worldwide

More than **20 years'** experience

Excellent survival rates¹

More than **200** scientific publications

Full solution including Neodent **Digital**

Innovative **Grand Morse implant** system

Excellent alternative to leading competitor systems

Available from the **Straumann Group**

Low cannibalization of Straumann

31


¹ After up to 5 years: Sartori IAM, Latenek RT, Budel LA, Thomé G, Bernardes SR, Tiozzi R. Retrospective analysis of 2244 implants and the importance of follow-up in implantology. Journal of Research in Dentistry. 2014 Nov-Dec;2(6):555-564.

straumanngroup


Bringing premium & non premium together to simplify and create selling opportunities



Target unexploited growth markets & segments



- Premium and non-premium sales teams able to offer full range of biomaterials & CAD/CAM solutions
- Simplification of internal processes and legal set-up
- Intradent activities now coordinated at regional level
- Approach tailored to local markets



32

straumanngroup

Digital Business Unit – a global powerhouse

Expand scope to become a Total Solution Provider for esthetic dentistry



33

straumanngroup

Digital on the road

Expand scope to become a Total Solution Provider for esthetic dentistry




Penetration levels	Dental practices	Dental laboratories
	Intra-oral scanners	Desktop scanners
US	15-20%	>65%
Germany	15-20%	>75%
China	<5%	25-30%
Brazil	<5%	25-30%

straumanngroup



 Expand scope to become a Total Solution Provider for esthetic dentistry


All-in-one digital solutions in North America



- Straumann-branded 3Shape TRIOS 3 intra-oral scanner now available in North America
- Accurate, ultra-fast, powder-free, full color; simplifies communication between dentist, lab, and milling center
- High-end chairside solution in combination with Straumann's compact C series mill
- TRIOS 3 integrated with ClearCorrect orthodontic solutions
- Complemented by the competitively-priced Dental Wings scanner range


straumanngroup

36


 Expand scope to become a Total Solution Provider for esthetic dentistry

Growth ambitions for our clear-aligner business


- Leverage Straumann sales organization
- Increase geographic reach
- Increase patient adoption
- Broaden indications
- Expand addressable market



37 straumanngroup

 Expand scope to become a Total Solution Provider for esthetic dentistry

Next steps for ClearCorrect




- NAM**
Exploit salesforce synergies between ClearCorrect & STMN
- Europe**
Pilots running in 4 countries to determine optimum sales approach; roll-out pilots to start in H2 2018
- ASIA**
Explore partnerships in China; initial activities in Japan & Singapore in H2
- LATAM**
Market launch in Brazil by Q1 2019

38 straumanngroup

Outlook 2018

straumanngroup

Plenty of growth potential in market segments collectively worth ~CHF 11 bn



40

straumanngroup

Our 2018 guidance

Barring unforeseen circumstances

Market growth


Global implant market to grow at approx. 4%

Our revenue growth

Confident to outperform and achieve organic revenue growth in the low double-digit range

Profitability

Further improvement in EBITDA margin;
EBIT margin stable



41

straumanngroup

Questions & answers

Q&A

straumanngroup

Annual Report 2017 – now online

43

straumanngroup

Calendar of upcoming events

2018	Event	Location
15 February	Full-year 2017 results conference	Straumann Group Headquarters, Basel
26 February	Investor meetings	London
06 March	Investor meetings	Toronto
07 March	Investor meetings	Boston
08 March	Investor meetings	Paris
22 March	Kepler Cheuvreux Conference	Zurich
04 April	AGM 2018	Messe Basel
26 April	Q1 revenue	Webcast
07 May	Investor meetings	Milano / Lugano
Social media	Type	Source
Analyst Talk (Shift + left mouse)	Executive interviewed by analysts	straumann.com (Investors) / youtube.com
StraumannIR (Shift + left mouse)	Investor Relations Twitter	@StraumannIR

Growth strategy pays off


in CHF m	2013	2014	2015	2016	2017	5-year average
Revenue	679.9	710.3	798.6	917.5	1112.1	
Organic revenue growth in %	1.2	6.4	9.1	13.1	15.7	9.1
Acquisition / Divestiture effect in %	-0.8	0.0	9.5	0.8	4.1	2.7
Change in l.c.%	0.4	6.4	18.6	13.9	19.8	11.8
FX effect in %	-1.3	-1.9	-6.1	1.0	1.4	-1.4
Growth in CHF %	-0.9	4.5	12.4	14.9	21.2	10.4
	2013	2014	2015	2016	2017	CAGR 2013-17
Gross profit b. exceptionals	535.9	558.7	628.0	718.5	842.4	12.0
Underlying margin	78.8%	78.7%	78.6%	78.3%	75.8%	
EBIT b. exceptionals	123.8	148.3	185.7	227.2	285.6	23.2
Underlying margin	18.2%	20.9%	23.3%	24.8%	25.7%	
Underlying net profit	107.9	130.9	144.7	186.8	237.2	21.8
Underlying margin	15.9%	18.4%	18.1%	20.4%	21.3%	
Earnings per share (adjusted)	6.98	8.42	9.19	11.94	15.13	21.3
	2013	2014	2015	2016	2017	CAGR 2013-17
Operating cash flow	151.5	146.2	185.6	184.7	217.3	9.4
Capital expenditure	(12.6)	(18.8)	(35.2)	(46.7)	(73.4)	
as % of revenue	-1.9%	-2.6%	-4.4%	-5.1%	-6.6%	
Free cash flow	139.2	128.4	151.1	138.7	144.7	1.0
Number of employees (year-end) ¹	2'217	2'387	3'471	3'797	4'881	21.8

¹ In March 2015, Straumann acquired the remaining 51% stake of Neodent (Brazil), which added 930 employees to the Group. In 2017, the incorporation of Equinox, Medentika, Dental Wings, ClearCorrect added 479 employees, while the remainder came through internal expansion, mainly in Brazil, Switzerland and the US, largely in production.

45


straumanngroup

Straumann's currency exposure



Average exchange rates (rounded)				FX sensitivity (+/- 10%) on full-year...		
		2016	2017	Latest trend	Revenue	EBIT
1	EURCHF	1.09	1.11	→	+/- 35m	+/- 21m
1	USDCHF	0.99	0.98	↘	+/- 29m	+/- 14m
100	BRLCHF	28.37	30.68	→	+/- 11m	+/- 3m
100	JPYCHF	0.90	0.88	→	+/- 6m	+/- 4m

Development of Straumann's main exchange rates since 2015



46

¹ These distribution charts represent the total net revenues and the total COGS, as well as OPEX in the various currencies. All numbers are rounded and based on FY 2017 figures as well as average FX rates in 2017. They also include Medentika, which was consolidated on 1 January 2017.

straumanngroup

